주식 : Astellas Pharma's groundbreaking drug, Padcev (active ingredient: Enfortumab vedotin/EV), is poised to redefine the treatment landscape for urothelial carcinoma. Professor In-Ho Kim, from the Oncology Department at Catholic University of Korea Seoul St. Mary's Hospital, presented the clinical significance of Padcev, the first antibody-drug conjugate (ADC) approved for both localized (LA) and metastatic (M) urothelial carcinoma (UC) during the Korean Society of Medical Oncology (KSMO) conference held at the Grand Walkerhill Seoul Hotel on September 7th.

재원 : Professor In-Ho Kim highlighted the increasing prevalence of bladder cancer in South Korea, affecting approximately 5,000 new cases each year, particularly among men, smokers, and the elderly population.

Currently, first-line treatments primarily include platinum-based chemotherapy and the immune checkpoint inhibitor "Keytruda (active ingredient: Pembrolizumab)," which is approved but awaits reimbursement.

Professor In-Ho Kim explained that Padcev is an ADC therapy targeting the cell surface protein Nectin-4, expressed in UC. Importantly, Padcev remains effective irrespective of Nectin-4 expression, eliminating the need for pre-biomarker testing.

Nectin-4 is characterized by low expression in healthy cells but significantly higher expression in UC, present in approximately 80% of UC cells and around 60% of bladder cancer cases.

Professor Kim emphasized that Padcev's approval has transformed the landscape of second-line treatments, replacing options like chemotherapy and immunotherapy.